https://doi.org/10.1016/s1470-2045(24)00100-1
Y
Yungan Tao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
186
Papers
5.4K
Citations
40
h-index
94
i10-index
Yungan Tao is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Head and Neck Cancer Studies & Head and Neck Surgical Oncology & Lung Cancer Treatments and Mutations. The author has an h-index of 40, co-authored 159 publications.
ORCID: 0000-0002-6916-5263Papers by this author
worksPembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2024 · The Lancet Oncology · 181 citations
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2024 · The Lancet Oncology · 181 citations
https://doi.org/10.1016/s1470-2045(24)00100-1
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
2022 · Annals of Oncology · 168 citations
https://doi.org/10.1016/j.annonc.2022.10.006
International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma
2021 · International Journal of Radiation Oncology*Biology*Physics · 96 citations
https://doi.org/10.1016/j.ijrobp.2021.01.041
Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412
2020 · Future Oncology · 58 citations
https://doi.org/10.2217/fon-2020-0184
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
2023 · European Journal of Cancer · 48 citations
https://doi.org/10.1016/j.ejca.2022.12.015
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat